Eli Lilly (NYSE: LLY) to acquire AtaiBeckley in $3.8bn TRD psychedelic deal

Eli Lilly and Company (NYSE: LLY), the Indianapolis-based pharmaceutical company, has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), the clinical-stage neuropsychiatry biotech formed from the 2024 combination of Atai Life Sciences and Beckley Psytech, in a definitive transaction worth up to approximately $3.8 billion. Under the terms disclosed on 16 July 2026, Lilly will pay $6.75 per share in cash on closing, representing an aggregate upfront equity value of approximately $2.8 billion, plus up to $2.50 per share in Contingent Value Rights tied to three specified development and regulatory milestones for the BPL-003 and VLS-01 programs. The upfront price represents approximately a 40 percent premium to AtaiBeckley’s 30-day volume-weighted average trading price through 15 July 2026, but sits materially below the consensus analyst price target range that had reflected the standalone commercial upside of a successful BPL-003 Phase 3 outcome. The deal is expected to close in the third quarter of 2026, is not subject to any financing condition, and represents Lilly’s ninth major acquisition of 2026, following disclosed transactions across vaccines, sleep therapeutics and cell therapy that have taken the group’s pledged upfront acquisition spend past $10 billion year-to-date.

The central tension is that Lilly is buying meaningful optionality on a Phase 3 read that will not deliver topline data until approximately 2029, at a valuation that captures material development risk transfer from public shareholders to the acquirer, while public shareholders forgo the standalone bull-case commercial upside if BPL-003 succeeds and receives both FDA approval and DEA rescheduling.

What did Lilly and AtaiBeckley actually agree, and how does the $6.75 upfront plus $2.50 CVR structure work?

The 16 July 2026 announcement structures the transaction as an upfront cash payment plus a CVR tied to three specific milestones. Lilly will pay $6.75 per share in cash on closing for each outstanding share of AtaiBeckley common stock, yielding an aggregate upfront equity value of approximately $2.8 billion. In addition, each AtaiBeckley share carries a Contingent Value Right entitling the holder to up to $2.50 in additional cash if specified milestones are achieved: $1.00 per share upon the initiation of a Phase 3 clinical trial of VLS-01 prior to the fourth anniversary of closing; $0.50 per share upon United States regulatory approval and Drug Enforcement Administration rescheduling of BPL-003 prior to the fifth anniversary of closing; and $1.00 per share upon United States regulatory approval and DEA rescheduling of VLS-01 prior to the seventh anniversary of closing. The CVR represents up to $1.0 billion in additional aggregate consideration.

Lilly and AtaiBeckley expressly disclosed that there can be no assurance that any of the CVR payments will be made. Apeiron Investment Group, Ltd., the family office of AtaiBeckley chairman and largest shareholder Christian Angermayer, together with all directors and officers of AtaiBeckley, have signed voting and support agreements covering approximately 15 percent of outstanding AtaiBeckley common stock. Goldman Sachs is exclusive financial advisor to Lilly and Ropes and Gray is legal counsel. Moelis and Company and Centerview Partners are financial advisors to AtaiBeckley, with Latham and Watkins as legal counsel. Citi provided separate financial advice to the AtaiBeckley board.

Why the 40% premium sits below analyst consensus for AtaiBeckley on a standalone basis

The $6.75 upfront cash consideration represents approximately a 40 percent premium to AtaiBeckley’s 30-day volume-weighted average trading price through 15 July 2026. That is a materially higher premium than typical for a biotech acquisition at this stage of clinical development, but the premium is calculated against a price that had already benefited from significant analyst upgrades and index inclusion during the first half of 2026. AtaiBeckley shares had climbed from approximately $3.30 to $3.90 through late March 2026 to trade in the $5 to $5.50 range through July, on catalysts including the Phase 3 initiation of the BPL-003 ReConnection program, positive peer-reviewed Phase 2a results published in CNS Drugs, and inclusion in the S and P Total Market Index, S and P Completion Index and CRSP United States benchmarks. Consensus analyst price targets prior to the deal announcement averaged approximately $13.33, with individual targets ranging from $10 at Jefferies to $16 at Guggenheim to $25 at H.C. Wainwright.

The Lilly upfront price at $6.75, and the maximum combined consideration of $9.25 including all CVR milestones, therefore sits below the analyst target midpoint and materially below the upper end. For AtaiBeckley shareholders, the trade is between certain cash today plus contingent upside on specific milestones, versus retaining the standalone risk and reward of BPL-003 Phase 3 development through to 2029 and beyond.

How BPL-003 and VLS-01 fit into Lilly’s expanding neuroscience pipeline strategy

BPL-003 is a synthetic form of 5-methoxy-N,N-dimethyltryptamine, also known as 5-MeO-DMT or mebufotenin, formulated as an intranasal spray for treatment-resistant depression. In a Phase 2a study reported in peer-reviewed CNS Drugs, a single 10 milligram dose produced a mean 12.6 point reduction in the Montgomery-Asberg Depression Rating Scale by Day 2, sustained to Day 85. The response rate at 50 percent or greater reduction was 54.5 percent through Day 85, and 63.6 percent of patients achieved remission at one or more timepoints. In a Phase 2b study, BPL-003 demonstrated rapid and durable reductions in depressive symptoms following an in-clinic visit lasting approximately two hours, with beneficial effects persisting for months. The compound holds Breakthrough Therapy Designation from the United States Food and Drug Administration and has initiated Phase 3 activities in the two-study ReConnection programme. Phase 3 topline results are expected in approximately 2029.

VLS-01 is a buccal film formulation of N,N-Dimethyltryptamine in an ongoing Phase 2b Elumina study, with 156 patients randomised and topline results expected in the fourth quarter of 2026. Both compounds address the interventional psychiatry treatment paradigm, in which a single dose administered in a clinical setting produces rapid and durable effect, rather than the daily oral dosing model of conventional antidepressants. For Lilly, the acquisition expands the neuroscience pipeline into rapid-acting neuroplastogen therapies, complementing the company’s existing Alzheimer’s disease franchise anchored by donanemab, marketed as Kisunla, and the broader Lilly Neuroscience portfolio.

What the DEA rescheduling milestones mean for the CVR payout economics

The CVR structure is worth analysing in commercial detail because it explicitly conditions payment on DEA rescheduling of both BPL-003 and VLS-01. 5-MeO-DMT and DMT are currently classified as Schedule I controlled substances by the United States Drug Enforcement Administration, meaning they are considered to have no accepted medical use and a high potential for abuse. For BPL-003 or VLS-01 to be commercially marketed after FDA approval, the DEA would need to reschedule the compounds, most likely into Schedule II or lower. That process is separate from the FDA approval process and follows its own procedural timeline. The precedent from esketamine, marketed by Johnson and Johnson as Spravato, provides one reference point: esketamine was scheduled III at FDA approval in 2019, but esketamine is chemically distinct from 5-MeO-DMT and DMT. There is not yet a directly comparable precedent for a Schedule I psychedelic being rescheduled following FDA approval.

The CVR structure therefore aligns AtaiBeckley shareholder economics with the full commercial pathway, not merely the FDA approval milestone. The trade-off is that the CVR payments are also subject to time limits: four years from closing for VLS-01 Phase 3 initiation, five years for BPL-003 approval and rescheduling, and seven years for VLS-01 approval and rescheduling. If those timelines slip, the corresponding CVR payments do not accrue. Lilly’s control of the development pace after closing therefore materially affects the ultimate value of the CVR to former AtaiBeckley shareholders.

How the deal lands within Lilly’s 2026 acquisition blitz beyond obesity and diabetes

The AtaiBeckley acquisition is the ninth major acquisition Lilly has announced during 2026, and the cumulative upfront acquisition spend now exceeds $10 billion. Prior transactions include Centessa Pharmaceuticals in the sleep therapeutics area for approximately $7.8 billion, Kelonia Therapeutics in cell therapy for up to $7 billion, and a combined vaccine platform position through the acquisitions of Curevo, LimmaTech Biologics and Vaccine Company for aggregate upfront consideration of approximately $3.8 billion. The pattern indicates that Lilly is deliberately diversifying its pipeline exposure beyond the current commercial anchors of the obesity and diabetes franchise, which is dominated by tirzepatide across Mounjaro for type 2 diabetes and Zepbound for obesity.

Lilly’s fiscal 2026 revenue trajectory continues to be driven substantially by tirzepatide sales, and the pace of acquisition activity is consistent with an intent to reduce single-molecule concentration risk while building durable positions across neuroscience, cell therapy, sleep and infectious disease vaccines. For neuroscience specifically, AtaiBeckley joins the donanemab-anchored Alzheimer’s disease franchise, and the pipeline commitment now includes rapid-acting interventional psychiatry, an area Lilly has not previously operated at scale. The strategic thesis is that ownership of the leading BPL-003 asset in treatment-resistant depression provides Lilly with the anchor around which to build a broader mental health portfolio at global commercial scale.

What the FDA rejection of MDMA-PTSD in 2024 signals about the interventional psychiatry regulatory bar

The interventional psychiatry regulatory environment carries a specific recent precedent that shapes the Phase 3 read-through for BPL-003 and VLS-01. In August 2024, the FDA rejected the New Drug Application submitted by Lykos Therapeutics for MDMA-assisted therapy for post-traumatic stress disorder, requesting an additional Phase 3 study before approval could be considered. The Lykos rejection was interpreted by the interventional psychiatry sector as reflecting FDA concerns about study blinding, functional unblinding of both patients and clinicians in psychedelic trials, therapy standardisation across sites, and long-term safety monitoring.

AtaiBeckley’s BPL-003 Phase 3 ReConnection programme has been designed with FDA End-of-Phase 2 alignment, and the two-study Phase 3 structure reflects specific FDA feedback on study design. For Lilly, the acquisition inherits both the strategic advantage of the FDA alignment already obtained and the residual regulatory risk that Phase 3 execution could nonetheless surface issues similar to those that affected the Lykos application. The CVR structure explicitly protects AtaiBeckley shareholders against Lilly deprioritising the programme, but does not protect against genuine regulatory setbacks. In the absence of a directly comparable Phase 3 approval precedent for a Schedule I psychedelic, the market has no established template for exactly how the ReConnection topline read in approximately 2029 will translate into approval outcomes.

What still needs to happen between announcement and closing in Q3 2026

Between the 16 July 2026 announcement and the expected third-quarter 2026 closing, several sequential steps must be completed. First, AtaiBeckley will file a preliminary proxy statement with the Securities and Exchange Commission, followed by definitive proxy materials mailed to shareholders. The definitive proxy will contain the merger agreement, background of the transaction, fairness opinion detail, forecasts, and the identity of any competing acquisition proposals received during the go-shop or fiduciary out periods. Second, AtaiBeckley stockholders will vote on the merger at a special meeting.

The 15 percent voting commitment from Apeiron Investment Group and directors and officers provides material voting support, but does not by itself guarantee approval. Third, regulatory clearances including Hart-Scott-Rodino Antitrust Improvements Act filings must be obtained. Given the market position of the transaction, the regulatory review is not expected to raise material antitrust concerns, but timing can extend to the outside date of the merger agreement. Fourth, any potential competing offer would need to emerge before the shareholder vote. Prior consensus analyst targets in the $13 to $16 range indicate that at least some analysts had valued AtaiBeckley above the Lilly upfront price, providing a theoretical basis for a competing bid. However, no such competing offer had been publicly disclosed at the time of the announcement.

Key takeaways from Lilly’s acquisition of AtaiBeckley and the neuroscience pipeline expansion

• Eli Lilly and Company has agreed to acquire AtaiBeckley Inc. for $6.75 per share in cash on closing, plus up to $2.50 per share in Contingent Value Rights, for potential aggregate consideration of approximately $3.8 billion.
• The upfront cash consideration values AtaiBeckley’s equity at approximately $2.8 billion and represents a 40 percent premium to AtaiBeckley’s 30-day volume-weighted average trading price through 15 July 2026.
• CVR milestones include $1.00 per share upon VLS-01 Phase 3 initiation, $0.50 per share upon BPL-003 FDA approval and DEA rescheduling, and $1.00 per share upon VLS-01 FDA approval and DEA rescheduling, each with time limits.
• BPL-003 is a synthetic 5-MeO-DMT intranasal formulation for treatment-resistant depression with FDA Breakthrough Therapy Designation; the Phase 3 ReConnection programme has been initiated with topline data expected in approximately 2029.
• VLS-01 is a DMT buccal film formulation with topline Phase 2b Elumina data expected in Q4 2026.
• Both compounds are currently DEA Schedule I controlled substances and would require DEA rescheduling in parallel with any FDA approval to be commercially marketable.
• The acquisition is Lilly’s ninth major acquisition of 2026 and takes cumulative pledged upfront acquisition spend past $10 billion for the year.
• Apeiron Investment Group and directors and officers of AtaiBeckley have signed voting agreements covering approximately 15 percent of outstanding shares.
• The deal is not subject to any financing condition and is expected to close in the third quarter of 2026, subject to AtaiBeckley stockholder approval and regulatory clearance.
• The FDA August 2024 rejection of Lykos Therapeutics’ MDMA-PTSD application remains the most recent regulatory precedent for interventional psychiatry and shapes the reading of the Phase 3 ReConnection outcome.